DrugPatentWatch Database Preview
OLUMIANT Drug Profile
When do Olumiant patents expire, and what generic alternatives are available?
Olumiant is a drug marketed by Eli Lilly And Co and is included in one NDA. There are two patents protecting this drug.
This drug has fifty-two patent family members in forty countries.
The generic ingredient in OLUMIANT is baricitinib. One supplier is listed for this compound. Additional details are available on the baricitinib profile page.
Summary for OLUMIANT
| International Patents: | 52 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 75 |
| Patent Applications: | 40 |
| Drug Prices: | Drug price information for OLUMIANT |
| Prior Art and Litigation Support | Order Prior Art and Litigation support for OLUMIANT |
| DailyMed Link: | OLUMIANT at DailyMed |
Generic Entry Opportunity Date for OLUMIANT
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Synonyms for OLUMIANT
| (1-(Ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)ethanenitrile |
| 1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile |
| 1187594-09-7 |
| 1231199-29-3 |
| 1374987-77-5 |
| 2-(3-(4-(3H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile |
| 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile |
| 2-[1-ETHYLSULFONYL-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PYRAZOL-1-YL]AZETIDIN-3-YL]ACETONITRILE |
| 3-Azetidineacetonitrile, 1-(ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)- |
| 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- |
| 3JW |
| AB0035958 |
| ABP001023 |
| AC-27404 |
| AJ-121247 |
| AKOS022186127 |
| AKOS025401933 |
| AM81232 |
| AMMD00005 |
| AOB87724 |
| AX8261519 |
| Baricitinib |
| Baricitinib (INCB28050 LY3009104) |
| Baricitinib (JAN/USAN/INN) |
| Baricitinib (LY3009104, INCB028050) |
| Baricitinib (LY3009104) |
| Baricitinib [USAN:INN] |
| BC600315 |
| BCP0726000031 |
| BCP9000380 |
| BDBM50021656 |
| C16H17N7O2S |
| CHEBI:95341 |
| CHEMBL2105759 |
| CS-0724 |
| D0Y7IC |
| D10308 |
| DB11817 |
| DS-7641 |
| DTXSID30152228 |
| EX-A413 |
| GTPL7792 |
| HMS3651L17 |
| HY-15315 |
| IN2285 |
| INCB 028050 |
| INCB 28050 |
| INCB-028050 |
| INCB-028050|||LY-3009104|||2-[1-Ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile |
| INCB-28050 |
| INCB028050 |
| INCB424-ANALOGUE |
| ISP4442I3Y |
| J-503551 |
| KB-74852 |
| KS-0000044L |
| LY 3009104 |
| LY-3009104 |
| LY3009104 |
| MLS006011247 |
| MolPort-023-219-125 |
| NCGC00345839-01 |
| Olumiant (TN) |
| PB27275 |
| QCR-197 |
| RL00725 |
| S-7686 |
| s2851 |
| SC-94301 |
| SCHEMBL871150 |
| SMR004703006 |
| UNII-ISP4442I3Y |
| XUZMWHLSFXCVMG-UHFFFAOYSA-N |
| Y0439 |
| ZINC73069247 |
US Patents and Regulatory Information for OLUMIANT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | OLUMIANT | baricitinib | TABLET;ORAL | 207924-001 | May 31, 2018 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Eli Lilly And Co | OLUMIANT | baricitinib | TABLET;ORAL | 207924-001 | May 31, 2018 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Eli Lilly And Co | OLUMIANT | baricitinib | TABLET;ORAL | 207924-001 | May 31, 2018 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for OLUMIANT
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Dominican Republic | P2010000270 | ➤ Sign Up |
| Costa Rica | 11640 | ➤ Sign Up |
| China | 102026999 | ➤ Sign Up |
| Eurasian Patent Organization | 017218 | ➤ Sign Up |
| Country | Patent Number | Estimated Expiration |
Supplementary Protection Certificates for OLUMIANT
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2288610 | 2017/032 | Ireland | ➤ Sign Up | PRODUCT NAME: BARACITINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF.; REGISTRATION NO/DATE: EU/1/16/1170 20170213 |
| 2288610 | 2017C/025 | Belgium | ➤ Sign Up | PRODUCT NAME: OLUMIANT - BARICITINIB; AUTHORISATION NUMBER AND DATE: EU/1/16/1170 20170215 |
| 2288610 | 122017000045 | Germany | ➤ Sign Up | PRODUCT NAME: BARICITINIB; REGISTRATION NO/DATE: EU/1/16/1170 20170213 |
| 2288610 | 17C0005 | France | ➤ Sign Up | PRODUCT NAME: BARICITINIB; REGISTRATION NO/DATE: EU/1/16/1170 20170215 |
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
